The CETI (Cell Enhancement and Technologies for Immunotherapy) Program is a multi-PI program led by:
- Dr. Catherine Bollard, Tenured Professor of Pediatrics & Microbiology, Immunology, and Tropical Medicine at GW
- Dr. Rohan Fernandes, Tenured Associate Professor at GW who leads the nanomedicine arm of our research
- Dr. Eric Yvon, Associate Professor at GW who also directs our GMP facility, which will generate clinical grade cell therapy products for trials
- Dr. Conrad Russell Cruz, Assistant Professor at GW, who leads our pre-clinical studies in the GW Cancer Center.
The CETI Program is housed within the Cancer Center at The George Washington University School of Medicine and Health Sciences. Our lab focuses on combining nanomedicine and gene-modified cell-based immunotherapies for targeting cancer and infectious disease. Our sister CETI lab is located at the Children’s National Health System in Washington, D.C.
Our projects include developing antigen-specific T cells to target infection; gene-modifying lymphocytes to increase cytotoxicity against tumors, decrease immunosuprression, or secrete broadly-neutralizing antibodies against HIV; and using nanoparticles to enhance immune cell effector function and drug delivery.